Long-term effects of hematopoietic growth factors in aplastic anemia patients treated with immunosuppression: Meta-analysis of randomized controlled trials. Issue 42 (21st October 2022)

• Record Type: Journal Article
• Authors: Wang, Anzi; Su, Dongyun; Luo, Jingyuan; Fu, Yuhan; Li, Qing; Chen, Shu
• Is Part Of: Medicine. Volume 101:Issue 42(2022)
• Page Start: e31103
• Publication Date: 2022-10-21
• Subjects: aplastic anemia -- hematopoietic growth factors -- immunosuppressive therapy -- meta-analysis; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000031103
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract : Background and purpose: Immunosuppressive therapy is the frontline treatment for aplastic anemia patients ineligible for transplantation. The long-term effects of hematopoietic growth factors (HGF) added to standard immunosuppressive therapy are still unclear. We performed a systematic review and meta-analysis to clarify this issue. Methods: A comprehensive search of databases was conducted including 5 international electronic databases (Cochrane, PubMed, Embase, Web of Science, and LILACS) and 4 Chinese electronic databases (Chinese Bio-medicine Database, Chinese National Knowledge Infrastructure, WanFang Data, and China Science and Technology Journal Database databases) from database inception until February, 2022. We included randomized controlled trials that assigned patients with acquired aplastic anemia treated with immunosuppressive therapy (IST), which compared between the addition of HGF and placebo or no treatment. The co-primary outcome were the overall survival (OS) and late clonal malignant evolution at the end of follow-up. Results: Nine randomized controlled trials including 719 participants were identified. The addition of growth factors to immunosuppression yielded no difference in OS (relative risks [RR], 1.08, 95% confidence interval [CI] 0.99–1.18). HGF was not associated with higher occurrence of secondary myelodysplastic syndromes/acute myeloid leukemia (RR, 1.09, 95% CI 0.43–2.78) or paroxysmal nocturnal hemoglobulinemia (RR, 1.38, 95% CI 0.68–2.81) at the end of follow-up. No difference were found in overall response (RR, 1.16, 95% CI 0.98–1.37), infections occurrence (RR, 0.82; 95% CI, 0.51–1.31) or relapse (RR, 0.65; 95% CI, 0.37–1.13). Conclusions: HGF as an adjunct to IST has no impact on long-term OS, late clonal malignant evolution, response rate, relapse or infections occurrence. HGF could be added to standard IST for high-risk patients with delayed neutrophil recovery without concern for long-term consequences but could not be recommended as routine clinical practice. Trial registration number: PROSPERO CRD42021275188.